EP 51389

Drug Profile

EP 51389

Latest Information Update: 07 Feb 2005

Price : $50

At a glance

  • Originator Ardana Bioscience
  • Class
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Somatotropin deficiency

Most Recent Events

  • 07 Feb 2005 No development reported - Preclinical for Somatotropin deficiency in France (PO)
  • 25 Aug 2002 Europeptides has been acquired from Zentaris AG by Ardana Bioscience
  • 02 Jun 2000 Preclinical development for Somatotropin deficiency in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top